Fernando Bianco, MD
Urology · Hialeah, FLNPI 1629169552
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 56 manufacturers reported payments, led by Angiodynamics, Inc. at 30.6% of the total. Reporting peaked in 2023 at $8,531 and has fallen 64.6% since, to $3,018 in 2025.
Across 580 payments — averaging $40.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$7K
- Janssen Scientific Affairs, LLC$2K
- Johnson & Johnson$2K
- Astellas Pharma US Inc$2K
- Intuitive Surgical$1K
- Janssen Research & Development, LLC$1K
- plus $8K from 50 others
Across 384 payments — averaging $5774.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$893K
- Merck$756K
- Pfizer$255K
- Clinical Laserthermia Systems Americas Inc.$164K
- AstraZeneca$90K
- Urovant Sciences Inc$25K
- plus $35K from 3 others
What the payments were for
- Consulting fees$7,33231%
- Travel & lodging$2,61611%
- Food & beverage$12,78755%
- Education$6763%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,411 in reported general payments places this provider in the 85th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 112 | $1,668,230 |
| XtandiEnzalutamide | 65 | $921,793 |
| NubeqaDarolutamide | 12 | $163,731 |
| GemtesaVibegron | 255 | $152,267 |
| MyrbetriqMirabegron | 123 | $63,225 |
| Tadalafil | 218 | $27,327 |
| ElmironPentosan Polysulfate Sodium | 22 | $20,231 |
| PremarinEstrogens, Conjugated | 34 | $14,752 |
| LinzessLinaclotide | 23 | $11,777 |
| CefuroximeCefuroxime Axetil | 227 | $6,849 |
| Tamsulosin Hcl | 803 | $4,540 |
| Potassium Citrate ErPotassium Citrate | 56 | $3,734 |
| Testosterone | 17 | $3,616 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 96 | $2,751 |
| NitrofurantoinNitrofurantoin Macrocrystal | 67 | $2,743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $1,959 | $1,668,230112 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $1,617 | $985,018188 claims |
| BayerNubeqa | $284 | $163,73112 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $417 | $152,267255 claims |
| PfizerPremarin | $912 | $14,75234 claims |
| AbbVieLinzess | $482 | $11,77723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 935 urology providers in Florida.
Other urology in Hialeah
- Edward GheilerHialeah$655K
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
- Juan SuarezCoral Gables$276K
- Michael McDonaldCelebration$272K
- Raymond PakJacksonville$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.